Group 1 - Protagonist Therapeutics reported a quarterly loss of $0.19 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.50, representing an earnings surprise of 62% [1] - The company posted revenues of $28.32 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 149.90%, compared to year-ago revenues of $254.95 million [2] - Protagonist Therapeutics shares have increased by approximately 14.7% since the beginning of the year, contrasting with the S&P 500's decline of -3.9% [3] Group 2 - The current consensus EPS estimate for the upcoming quarter is -$0.56 on revenues of $11.33 million, and for the current fiscal year, it is -$1.23 on revenues of $97.8 million [7] - The Medical - Biomedical and Genetics industry, to which Protagonist Therapeutics belongs, is currently ranked in the top 31% of over 250 Zacks industries, indicating a favorable outlook [8]

Peptide Therapeutics Development - The company is focused on peptide therapeutics, with two novel peptides, icotrokinra and rusfertide, in advanced Phase 3 clinical development, with potential NDA submissions to the FDA in 2025 [91]. - Icotrokinra has shown significant clinical improvement in treating moderate-to-severe plaque psoriasis, with a PASI-90 response rate of 74% at Week 24 compared to 8% in the placebo group (P<0.001) in the ICONIC-LEAD trial [101]. - The Phase 2b Anthem-UC trial of icotrokinra met its primary endpoint of clinical response at Week 12, with a response rate of 63.5% for the highest dose compared to 27.0% for placebo (p<0.001) [102]. - The ICONIC-ASCEND trial will be initiated to demonstrate the superiority of icotrokinra compared to ustekinumab, an injectable biologic [98]. - Rusfertide is in Phase 3 development for the treatment of Polycythemia Vera (PV) with 293 patients enrolled in the VERIFY trial, which has shown a 77% clinical response rate compared to 33% for placebo [109][112]. - The primary endpoint of the VERIFY trial was met with statistical significance (p<0.0001), showing a mean of 0.5 phlebotomies per patient in the rusfertide arm versus 1.8 in the placebo arm [112]. - The company plans additional clinical studies of icotrokinra in ulcerative colitis and Crohn's disease [103]. - PN-881, a potential best-in-class oral peptide IL-17 antagonist, has been selected for development, with a Phase 1 study expected to initiate in Q4 2025 [107]. Financial Performance and Revenue - The company earned a total of $337.5 million in non-refundable payments from JNJ from inception in 2017 through March 31, 2025, and is eligible for up to $630.0 million in future milestone payments [105]. - License and collaboration revenue for the three months ended March 31, 2025, was $28.3 million, a decrease of 89% compared to $255 million in the same period in 2024 [134]. - License and collaboration revenue for Q1 2025 was $28.3 million, including $22.8 million from a milestone related to the Phase 3 VERIFY trial of rusfertide [136]. - For Q1 2024, license and collaboration revenue was $255.0 million, primarily from a $300.0 million upfront payment for the rusfertide license to Takeda [137]. - Cumulative net losses from inception through March 31, 2025, amount to $352.2 million, primarily due to research and development costs [120]. - The company expects revenue in 2025 to decrease significantly compared to 2024, primarily due to lower milestone achievements [140]. Research and Development Expenses - Research and development expenses for the three months ended March 31, 2025, were $35.9 million, an increase of 6% from $33.7 million in 2024 [134]. - Research and development expenses increased by $2.2 million, or 6%, from $33.7 million in Q1 2024 to $35.9 million in Q1 2025, driven by a $5.3 million increase in pre-clinical and drug discovery research expenses [141]. - The company anticipates continued significant research and development expenses as it prepares for regulatory filings and commercialization of rusfertide [130]. Cash and Financing Activities - Cash provided by operating activities for Q1 2025 was $125.4 million, significantly up from a cash used of $27.4 million in Q1 2024, primarily due to a $165.0 million milestone payment received [161]. - As of March 31, 2025, the company had $697.9 million in cash, cash equivalents, and marketable securities, up from $559.2 million at the end of 2024 [147]. - Cash provided by financing activities for Q1 2025 was $11.4 million, a $4.2 million increase compared to Q1 2024, primarily due to a $4.1 million increase in proceeds from stock issuance [163]. - The company had $697.9 million in cash, cash equivalents, and marketable securities as of March 31, 2025, up from $559.2 million at December 31, 2024 [166]. Collaborations and Agreements - Icotrokinra is co-developed with JNJ and Takeda, with the company primarily responsible for clinical development activities [92]. - The JNJ License and Collaboration Agreement was amended to increase milestone payments and eliminate certain previous milestone payments [108]. - The company received a one-time, non-refundable upfront payment of $300 million from Takeda under a collaboration agreement for rusfertide, with potential milestone payments of up to $305 million [111][114]. - Upcoming milestones under the Takeda agreement include tiered royalties of 10% to 17% on ex-U.S. net sales of rusfertide [114][115]. - Upcoming potential milestones under the Takeda Collaboration Agreement include a $50.0 million increase for a Phase 3 clinical trial milestone and various NDA approval milestones for rusfertide and icotrokinra [150][151][152]. Interest Income and Market Risks - Interest income increased by 73% to $7.6 million for the three months ended March 31, 2025, compared to $4.4 million in 2024 [134]. - Interest income rose by $3.2 million, or 73%, from $4.4 million in Q1 2024 to $7.6 million in Q1 2025, attributed to higher invested balances [145]. - An immediate 100 basis point increase in interest rates would increase annual interest income by approximately $3.4 million, while a decrease would have the same negative impact [166]. - The company is exposed to market risks, including interest rate sensitivities and inflation risk affecting labor and clinical trial costs [165]. Operational Insights - Inflation has not had a material adverse effect on the company's operations during Q1 2025 [168]. - There were no material changes to the company's cash requirements or commitments for capital expenditures during Q1 2025 [164]. - The company has not implemented a formal hedging program for foreign currency but may consider it if exposure increases significantly [167]. - The majority of expenses related to Australian operations are denominated in Australian dollars, while other expenses are generally in U.S. dollars [167]. - Approximately $1.3 million of the cash balance was located in Australia as of March 31, 2025, compared to $0.6 million at December 31, 2024 [167].

Financial Performance - License and collaboration revenue for the first quarter of 2025 was $28.3 million, compared to $255.0 million for the same period in 2024[12] - Net loss for the first quarter of 2025 was $11.7 million, or $0.19 per share, compared to net income of $207.3 million, or $3.41 per share, for the first quarter of 2024[15] - Total stockholders' equity as of March 31, 2025, was $689.1 million, compared to $675.3 million as of December 31, 2024[23] Cash Position - Cash, cash equivalents, and marketable securities as of March 31, 2025, were $697.9 million, up from $559.2 million as of December 31, 2024[9] - The company anticipates cash runway through at least the end of 2028 based on its current cash position[2] Research and Development - Research and development expenses increased to $35.9 million in Q1 2025 from $33.7 million in Q1 2024[12] - The Phase 3 VERIFY trial of rusfertide met its primary endpoint with a significantly higher proportion of clinical responders compared to placebo (p<0.0001) during weeks 20-32[7] - Positive topline results from the Phase 2b ANTHEM trial of icotrokinra in ulcerative colitis were announced, laying the foundation for further studies[2] - The full dataset from the Phase 3 ICONIC-LEAD trial with icotrokinra was presented at the 2025 AAD Meeting in March[1] - The company is focusing on advancing pre-clinical candidates, including the oral IL-17 antagonist PN-881, in 2025[2]

Earnings Report - Johnson & Johnson is set to release its first-quarter earnings results on April 15, with analysts expecting earnings of $2.58 per share, a decrease from $2.71 per share in the same period last year [1] - The company is projected to report quarterly revenue of $21.57 billion, up from $21.38 billion a year earlier [1] Product Development - Protagonist Therapeutics announced new data for a pill treating moderate-to-severe plaque psoriasis, with the study conducted in adolescents and adults [2] - The data from the ICONIC program, involving icotrokinra (JNJ-2113), was developed through a partnership with Johnson & Johnson [2] Analyst Ratings - Raymond James analyst maintained an Outperform rating but reduced the price target from $165 to $162 [7] - Morgan Stanley analyst kept an Equal-Weight rating and raised the price target from $163 to $164 [7] - Guggenheim analyst reiterated a Neutral rating [7] - Barclays analyst maintained an Equal-Weight rating and increased the price target from $159 to $166 [7] - Stifel analyst maintained a Hold rating and cut the price target from $170 to $155 [7]

Protagonist Therapeutics (PTGX) Update Summary Company Overview - Protagonist Therapeutics is focused on peptide therapeutics, with a history of 15-18 years in the field [4][5] - The company is advancing two late-stage assets towards NDA filing in 2025: Icotropinirap for psoriasis and Ruscotag for polycythemia vera (PV) [5][11] Industry Context - The presentation centers on the treatment of polycythemia vera (PV), a chronic myeloproliferative neoplasm characterized by the overproduction of red blood cells [25][26] - PV affects approximately 150,000-250,000 patients in the U.S., with a median age of diagnosis at 61 years [27][28] Key Points on Ruscotag (Ruspatercept) - Ruspatercept is being evaluated in multiple studies, with Phase III results expected in March 2025 [6][11] - The drug is a hepcidin mimetic aimed at reducing red blood cell production by blocking ferroportin, thus decreasing iron delivery to the bone marrow [52][53] - The PACIFIC Phase II study showed rapid hematocrit control, with 85% of patients achieving levels below 45% within eight weeks [56][58] - The REVIVE Phase II study demonstrated a significant response rate, with 69% of patients on ruspatercept not being phlebotomy eligible compared to 15% in the placebo group [73] Clinical Development and Pipeline - The clinical development plan includes three studies: PACIFIC, REVIVE, and the upcoming VERIFI Phase III study [20][21] - The VERIFI study is designed to evaluate the efficacy of ruspatercept against standard care, with a focus on maintaining hematocrit levels below 45% [91][92] Financial Position - Protagonist has a strong cash runway projected through the end of 2028, bolstered by partnerships with Johnson & Johnson and Takeda Pharmaceuticals [13][14] - Potential milestone earnings of $200 million to $600 million are anticipated, along with future royalties from the assets [14] Safety and Efficacy - The safety profile of ruspatercept is comparable to other studies, with injection site reactions being the most common adverse event [57][86] - Long-term safety data is being collected through the open-label extension of the REVIVE study, with a focus on maintaining patient adherence to therapy [88] Unmet Needs and Market Opportunity - There is a significant unmet need in the treatment of PV, with current therapies associated with risks of thrombosis and secondary malignancies [31][32][86] - Ruspatercept aims to address these needs by providing a new therapeutic option that can improve quality of life for patients [77][98] Conclusion - Protagonist Therapeutics is positioned to make a significant impact in the treatment of polycythemia vera with ruspatercept, supported by a robust clinical pipeline and strong financial backing [11][14]